To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Tipifarnib
Tipifarnib (Zarnestra) is a drug that is being investigated in patients 65 years of age and older with newly diagnosed acute myeloid leukemia (AML). Additional recommended knowledgeThe compound was discovered by and is under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C, with registration number R115777. |
||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tipifarnib". A list of authors is available in Wikipedia. |
- Scientists mix and match properties to make new superconductor with chiral structure - Fine tuning crystal symmetry and superconductivity using solid solution methods
- Analytica and ceramitec 2024 in parallel - Added value for exhibitors and visitors
- A better way of scrubbing CO2 - Berkeley Lab researchers find way to improve the cost-effectiveness through the use of MOFs
- Omega_Pharma